Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Novavax, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Sarepta's SG&A expenses grew by approximately 878%, while Novavax saw an astonishing increase of around 2,254%. Notably, in 2022, Novavax's expenses peaked at nearly 490 million, surpassing Sarepta's 451 million. This trend highlights the aggressive expansion and operational scaling of these companies, especially during the COVID-19 pandemic when Novavax was at the forefront of vaccine development. As these companies continue to innovate, understanding their financial strategies offers valuable insights into their market positioning and future growth potential.